Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis ...
Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.
Transcriptional profiling of patients with metastatic hormone-sensitive prostate cancer to uncover specific signatures linked to the transition from androgen-dependent to androgen-independent ...
Burnout in oncologists has been increasing, especially after the COVID-19 pandemic. This is concerning because burnout can have both personal and professional repercussions, as well as a negative ...
Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants. This is an ASCO Meeting Abstract from the 2025 ASCO ...
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...
Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors. PSMA-positive tumor vessels around renal cell carcinoma ...
Validation of new prognostic factors for relapse in patients with clinical stage I seminoma. Time to real-world progression (TTrwP) among patients (pts) with relapsed/refractory (R/R) testicular germ ...
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
Utility of extended interval dosing of denosumab in patients with metastatic prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results